Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zevorcabtagene autoleucel - CARsgen

Next Previous
X
Search
Drug Profile

Zevorcabtagene autoleucel - CARsgen

Alternative Names: Anti-BCMA CAR T cell therapy - CARsgen; BCMA-redirected autologous T cells-CARsgen; CAR BCMA T-cell therapy-CARsgen; CAR-BCMA T Cell Infusion; CT-053 - CARsgen; Zevor-cel

Latest Information Update: 05 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 05 Nov 2024 The US FDA liftes the clinical holds hold on clinical trials of zevorcabtagene autoleucel in USA
  • 13 Jun 2024 Adverse events and efficacy data from a phase I/II LUMMICAR STUDY 1 trial in Multiple Myeloma presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 15 Mar 2024 Launched for Multiple myeloma (Second-line therapy or greater) in China (IV) as of March 2024 - First Global Launch (CARsgen pipeline, March 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top